CDE Catalog

***Please contact the NINDS CDE Team (NINDSCDE@emmes.com) if you encounter any search difficulties.***

The CDE Catalog is a directory of the available NINDS CDEs. Users can search the Catalog to isolate a subset of the CDEs (e.g., all stroke-specific CDEs, etc.), and to view and download details about the CDEs.

Select any filter below to search the CDE Catalog.

For best results, clear form between searches. In addition, when specifying NeuroRehab, Sport-Related Concussion (SRC) or Traumatic Brain Injury (TBI) as the Disease, please select a Subdisease as well.

NeuroRehab Comprehensive includes all NeuroRehab CDE recommendations. NeuroRehab General includes all NeuroRehab CDE recommendations that are not disease specific. All other NeuroRehab Subdiseases include recommendations specific to existing NINDS CDE project disorders.

Choose your Time Frame for your SRC study (Acute (time of injury until 72 hours), Subacute (after 72 hours to 3 months), and Persistent/Chronic (3 months and greater post-concussion) or Comprehensive if your study falls across the study time frames.

Choose your type of TBI study (Acute Hospitalized, Concussion/Mild TBI, Moderate/Severe TBI: Rehabilitation, or Epidemiology) or Comprehensive if your study falls outside of the study types or incorporates aspects of more than one type of study.

Search Form

Displaying 301 - 325 of 1067
Operations
Selected 25 rows in this page.  
The search results below can be downloaded by clicking the checkboxes on the far left side of the table. Select the header checkbox to select all CDEs listed on the first page. Then choose CDE Detailed Report from the Choose an operation dropdown menu.
CDE ID CDE Name Definition Classification CRF Name Copyrighted or trademarked Disease Name Subdisease Name
C12232 Laboratory director name

Name of laboratory director where assessment was performed

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12449 Polysomnography end tidal carbon dioxide measurement grade

Grade of the end-tidal CO2 (ETCO2) measurements being reported

Supplemental Polysomnography Myasthenia Gravis Myasthenia Gravis (MG)
C12178 Dual X-ray absorptiometry hip T score

Dual X-ray absorptiometry (DEXA) Hip T score result value

Supplemental Dual-Energy X-Ray Absorptiometry (DEXA) Myasthenia Gravis Myasthenia Gravis (MG)
C12218 Gastrointestinal therapy formula name

Name of the formula taken by the participant/subject for non-continuous feeding

Supplemental Gastrointestinal Therapies Myasthenia Gravis Myasthenia Gravis (MG)
C12346 Respiratory lung volume recruitment breath per cycle count

Count of the number of breaths per cycle of lung volume recruitment device use

Supplemental Respiratory Interventions Myasthenia Gravis Myasthenia Gravis (MG)
C12457 Polysomnography transcutaneous carbon dioxide REM sleep value

Value, as a percent, of the selected transcutaneous CO2 (TcCO2) measurement during rapid eye movement (REM) sleep

Supplemental Polysomnography Myasthenia Gravis Myasthenia Gravis (MG)
C12186 Dual X-ray absorptiometry distal femur raw score

Dual X-ray absorptiometry (DEXA) distal femur raw score result value

Supplemental Dual-Energy X-Ray Absorptiometry (DEXA) Myasthenia Gravis Myasthenia Gravis (MG)
C12534 Gastrointestinal therapy formula grade

Grade, in cal/oz, of formula taken by the participant/subject if receiving continuous feeding

Supplemental Gastrointestinal Therapies Myasthenia Gravis Myasthenia Gravis (MG)
C17900 Age presentation year value

Age (in years) of participant/subject at presentation

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12281 Tissue abnormality myelin axon decrease status

Status of any observed decrease in the myelinated axon numbers of the epon-embedded tissue specimen

Supplemental Peripheral Nerves - Biopsies and Autopsies Myasthenia Gravis Myasthenia Gravis (MG)
C12403 Respiratory oxygen use schedule type

Type of schedule of supplemental oxygen use

Supplemental Respiratory Interventions Myasthenia Gravis Myasthenia Gravis (MG)
C17942 Spectroscopy sequence parameter PRESS asymmetry TE1 value

Value, in ms, of echo time (TE) 1 for an asymmetric PRESS sequence if used in the scan being reported

Supplemental Magnetic Resonance Spectroscopy (MRS) Myasthenia Gravis Myasthenia Gravis (MG)
C12361 Respiratory other airway clearance method use daily freq

Frequency of use of other airway clearance method on a daily basis

Supplemental Respiratory Interventions Myasthenia Gravis Myasthenia Gravis (MG)
C12539 Imaging fluid attenuated inversion recovery sequence indicator

Indicator of whether FLAIR (fluid attenuated inversion recovery) sequence was used to remove the effects of fluid from the resulting images

Supplemental Magnetic Resonance Imaging (MRI) Myasthenia Gravis Myasthenia Gravis (MG)
C12260 Biopsy and autopsy perivascular inflammation type

Evidence of vascular damage includes damaged vessels in association with perivascular inflammation and the presence of fibrin thrombi located within vascular spaces

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12231 Laboratory name

Name of laboratory where assessment was performed

Supplemental Fat Aspirate Tissue Specimens Myasthenia Gravis Myasthenia Gravis (MG)
C18838 Respiratory manual percussion use other text

The free-text field related to 'Respiratory manual percussion use frequency' specifying other text. Frequency of use of manual percussion therapy

Supplemental Respiratory Interventions Myasthenia Gravis Myasthenia Gravis (MG)
C17951 Spectroscopy sequence other type text

Text specification of unlisted spectroscopy sequences used in the scan being reported

Supplemental Magnetic Resonance Spectroscopy (MRS) Myasthenia Gravis Myasthenia Gravis (MG)
C12369 Respiratory airway clearance medication frequency

Value of the frequency the participant/subject uses the airway clearance medication

Supplemental Respiratory Interventions Myasthenia Gravis Myasthenia Gravis (MG)
C12268 Immunohistochemical stain used muscle biopsy and autopsy type

Which immunohistochemical stains were used on muscle biopsy?

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C18828 Histochemical stains used other text

The free-text field related to 'Histochemical stains used type' specifying other text. Type of standard histochemical stains used on the tissue specimen

Core Fat Aspirate Tissue Specimens Myasthenia Gravis Myasthenia Gravis (MG)
C18846 Respiratory other airway clearance method use other text

The free-text field related to 'Respiratory other airway clearance method use frequency' specifying other text. Frequency of use of other airway clearance methods

Supplemental Respiratory Interventions Myasthenia Gravis Myasthenia Gravis (MG)
C12294 Laboratory pathology normal range

Range of intraepidermal nerve fiber density that is considered normal at the pathology laboratory examining the tissue specimen

Supplemental Skin Biopsies for Qualification of Intraepidermal Nerve Fibers Myasthenia Gravis Myasthenia Gravis (MG)
C10584 Imaging phase resolution percentage value

The value in percent of the phase resolution used in imaging acquisition

Supplemental Diffusion Tensor Imaging (DTI) Myasthenia Gravis Myasthenia Gravis (MG)
C18814 Spectroscopy water suppression other text

The free-text field related to 'Spectroscopy water suppression type' specifying other text. Indicator of water suppression method used, if any, for the spectroscopy scan being reported

Supplemental Magnetic Resonance Spectroscopy (MRS) Myasthenia Gravis Myasthenia Gravis (MG)
Displaying 301 - 325 of 1067

The NINDS CDE Team does not post proprietary instruments/scales recommended by the CDE Working Groups on this website. This includes, but is not limited to, copyrighted or trademarked instruments/scales. Information about recommended instruments can be found in the Notice of Copyright (NOC) documents under ‘CRF Module/Guideline’ on each disorder’s data standards page. For any questions regarding these instruments/scales please contact the corresponding owner/author. The NINDS CDE Team is not responsible for the availability or content of these external sites, nor does the NINDS CDE Team endorse, warrant or guarantee the products, services or information described or offered at these other internet sites.